15 May 2026 - The MHRA has today approved beremagene geperpavec (Vyjuvek) for the treatment of wounds in patients with dystrophic epidermolysis bullosa. It can be used from birth onward.

This product was submitted and approved via International Recognition Procedure.

Read UK Government press release